User menu

Long-term safety and efficacy of epratuzumab in the treatment of moderate-to-severe systemic lupus erythematosus: results from an open-label extension study.

Bibliographic reference Wallace, Daniel J ; Hobbs, Kathryn ; Clowse, Megan E B ; Petri, Michelle ; Strand, Vibeke ; et. al. Long-term safety and efficacy of epratuzumab in the treatment of moderate-to-severe systemic lupus erythematosus: results from an open-label extension study.. In: Arthritis Care & Research, Vol. 68, no. 4, p. 534-543 (2016)
Permanent URL http://hdl.handle.net/2078.1/169057
  1. Flower, Arthritis Care Res (Hoboken), 64, 1151 (2012)
  2. Rheumatology (2003)
  3. Shah Manan, Chaudhari Sham, McLaughlin Trent P., Kan Hong J., Bechtel Benno, Dennis Gregory J., Molta Charles T., Cumulative Burden of Oral Corticosteroid Adverse Effects and the Economic Implications of Corticosteroid Use in Patients With Systemic Lupus Erythematosus, 10.1016/j.clinthera.2013.03.001
  4. THAMER M., HERNAN M. A., ZHANG Y., COTTER D., PETRI M., Prednisone, Lupus Activity, and Permanent Organ Damage, 10.3899/jrheum.080828
  5. Sanz Iñaki, Lee F. Eun-Hyung, B cells as therapeutic targets in SLE, 10.1038/nrrheum.2010.68
  6. Dörner Thomas, Giesecke Claudia, Lipsky Peter E, Mechanisms of B cell autoimmunity in SLE, 10.1186/ar3433
  7. Furie Richard, Petri Michelle, Zamani Omid, Cervera Ricard, Wallace Daniel J., Tegzová Dana, Sanchez-Guerrero Jorge, Schwarting Andreas, Merrill Joan T., Chatham W. Winn, Stohl William, Ginzler Ellen M., Hough Douglas R., Zhong Z. John, Freimuth William, van Vollenhoven Ronald F., , A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus, 10.1002/art.30613
  8. Navarra Sandra V, Guzmán Renato M, Gallacher Alberto E, Hall Stephen, Levy Roger A, Jimenez Renato E, Li Edmund K-M, Thomas Mathew, Kim Ho-Youn, León Manuel G, Tanasescu Coman, Nasonov Eugeny, Lan Joung-Liang, Pineda Lilia, Zhong Z John, Freimuth William, Petri Michelle A, Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial, 10.1016/s0140-6736(10)61354-2
  9. Dörner Thomas, Shock Anthony, Smith Kenneth G.C., CD22 and Autoimmune Disease, 10.3109/08830185.2012.709890
  10. Carnahan, Clin Cancer Res, 9, 3982S (2003)
  11. Sieger N., Fleischer S. J., Mei H. E., Reiter K., Shock A., Burmester G. R., Daridon C., Dörner T., CD22 ligation inhibits downstream B cell receptor signaling and Ca2+flux upon activation, 10.1002/art.37818
  12. Traczewski Pawel, Rudnicka Lidia, Treatment of systemic lupus erythematosus with epratuzumab : Treatment of systemic lupus erythematosus with epratuzumab, 10.1111/j.1365-2125.2010.03767.x
  13. Rossi E. A., Goldenberg D. M., Michel R., Rossi D. L., Wallace D. J., Chang C.-H., Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab, 10.1182/blood-2012-12-473744
  14. Wallace Daniel J, Kalunian Kenneth, Petri Michelle A, Strand Vibeke, Houssiau Frederic A, Pike Marilyn, Kilgallen Brian, Bongardt Sabine, Barry Anna, Kelley Lexy, Gordon Caroline, Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study, 10.1136/annrheumdis-2012-202760
  15. Fleischer, Arthritis Rheumatol, 66, S856 (2014)
  16. Giltiay, Arthritis Rheumatol, 66, S855 (2014)
  17. Dean G. S, Cytokines and systemic lupus erythematosus, 10.1136/ard.59.4.243
  18. Wallace Daniel J., Gordon Caroline, Strand Vibeke, Hobbs Kathryn, Petri Michelle, Kalunian Kenneth, Houssiau Frederic, Tak Paul P., Isenberg David A., Kelley Lexy, Kilgallen Brian, Barry Anna N., Wegener William A., Goldenberg David M., Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up, 10.1093/rheumatology/ket129
  19. Strand V., Petri M., Kalunian K., Gordon C., Wallace D. J., Hobbs K., Kelley L., Kilgallen B., Wegener W. A., Goldenberg D. M., Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006, 10.1093/rheumatology/ket378
  20. Gladman, J Rheumatol, 29, 288 (2002)
  21. Yee Chee-Seng, Cresswell Lynne, Farewell Vernon, Rahman Anisur, Teh Lee-Suan, Griffiths Bridget, Bruce Ian N., Ahmad Yasmeen, Prabu Athiveeraramapandian, Akil Mohammed, McHugh Neil, D’Cruz David, Khamashta Munther A., Isenberg David A., Gordon Caroline, Numerical scoring for the BILAG-2004 index, 10.1093/rheumatology/keq026
  22. Wallace, Arthritis Rheum, 63, 2265 (2011)
  23. Strand, Am J Manag Care, 14, 234 (2008)
  24. Strand V, Crawford B, Singh J, Choy E, Smolen J S, Khanna D, Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases, 10.1136/ard.2009.115550
  25. Strand Vibeke, Mease Philip, Burmester Gerd R, Nikaï Enkeleida, Coteur Geoffroy, van Vollenhoven Ronald, Combe Bernard, Keystone Edward C, Kavanaugh Arthur, Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial, 10.1186/ar2859
  26. Strand Vibeke, Singh Jasvinder A., Newer Biological Agents in Rheumatoid Arthritis : Impact on Health-Related Quality of Life and Productivity, 10.2165/11531980-000000000-00000
  27. Strand, Arthritis Rheum, 65, S1080 (2013)
  28. Neville, J Rheumatol, 27, 675 (2000)
  29. Jolly Meenakshi, Garris Cindy P., Mikolaitis Rachel A., Jhingran Priti M., Dennis Greg, Wallace Daniel J., Clarke Ann, Dooley Mary Anne, Parke Ann, Strand Vibeke, Alárcon Graciela S., Kosinski Mark, Development and Validation of the Lupus Impact Tracker: A Patient-Completed Tool for Clinical Practice to Assess and Monitor the Impact of Systemic Lupus Erythematosus : Lupus Impact Tracker, 10.1002/acr.22349
  30. Jolly Meenakshi, Pickard A. Simon, Block Joel A., Kumar Rajan B., Mikolaitis Rachel A., Wilke Caitlyn T., Rodby Roger A., Fogg Louis, Sequeira Winston, Utset Tammy O., Cash Thomas F., Moldovan Iona, Katsaros Emmanuel, Nicassio Perry, Ishimori Mariko L., Kosinsky Mark, Merrill Joan T., Weisman Michael H., Wallace Daniel J., Disease-Specific Patient Reported Outcome Tools for Systemic Lupus Erythematosus, 10.1016/j.semarthrit.2011.12.005
  31. McElhone Kathleen, Abbott Janice, Shelmerdine Joanna, Bruce Ian N., Ahmad Yasmeen, Gordon Caroline, Peers Kate, Isenberg David, Ferenkeh-Koroma Ada, Griffiths Bridget, Akil Mohamed, Maddison Peter, Teh Lee-suan, Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus, 10.1002/art.22881